Completed PHASE1 INTERVENTIONAL NCT00008073

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

Phase I Study Of Octreotide Acetate (Sandostatin) (SMS) As A Biomodulator Of Doxorubicin (DOX)

Sponsor: National Cancer Institute (NCI)

Conditions Unspecified Adult Solid Tumor, Protocol Specific

Interventions doxorubicin hydrochloride octreotide acetate

Updated 6 times since 2017 Last updated: Dec 18, 2013 Started: Jan 31, 1996 Primary completion: May 31, 2002 Completion: May 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Unspecified Adult Solid Tumor, Protocol Specific and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Pittsburgh

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States